NCT06701513 A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
| NCT ID | NCT06701513 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bristol-Myers Squibb |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2025-01-29 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2025-01-29 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Eligibility Criteria
Inclusion Criteria: * ≥18 years of age * Physician-reported diagnosis of moderate to severe plaque psoriasis * Be newly initiating deucravacitinib * Do not object to participate Exclusion Criteria: * Currently participating in or planning to participate in an interventional clinical trial * Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
Contact & Investigator
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
✉ Clinical.Trials@bms.com📞 855-907-3286
Bristol-Myers Squibb
STUDY DIRECTOR
Bristol-Myers Squibb
Frequently Asked Questions
Who can join the NCT06701513 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06701513 currently recruiting?
Yes, NCT06701513 is actively recruiting participants. Contact the research team at Clinical.Trials@bms.com for enrollment information.
Where is the NCT06701513 trial being conducted?
This trial is being conducted at Amiens, France, Angers, France, Argenteuil, France, Argenteuil, France and 11 additional locations.
Who is sponsoring the NCT06701513 clinical trial?
NCT06701513 is sponsored by Bristol-Myers Squibb. The principal investigator is Bristol-Myers Squibb at Bristol-Myers Squibb. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.